Drug therapy: Hepatitis B virus infection

New England Journal of Medicine

Volumn 359, Issue 14, 2008, Pages 1486-1500

  Dienstag, Jules L ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ANXIETY; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BONE MARROW SUPPRESSION; DEPRESSION; DISEASE COURSE; FLU LIKE SYNDROME; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HUMAN; INCIDENCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; DISEASE TRANSMISSION; DRUG COMBINATION; GENETICS; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; ONSET AGE; PHYSIOLOGY;

AGE OF ONSET; ANTIVIRAL AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; VIRUS REPLICATION;

EID: 54849146600     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra0801644     Document Type: Review

References (117)

1. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976;295:517-22.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
3. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-53.
4. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-29. [Erratum, N Engl J Med 2004;351:351.]
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. [Erratum, Hepatology 2007;45:1347.]
6. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056-75.
7. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986;232:477-84.
8. Dienstag JL, Isselbacher KJ. Acute viral hepatitis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 16th ed. Vol. 2. New York: McGraw-Hill, 2005:1822-38.
9. Beasley RP, Hwang L-Y, Lin C-C, Chien C-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33.
10. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:Suppl 1:S173-S181.
11. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47:760-7.
12. Nguyen MH, Trinh H, Garcia RT, Ahmed A, Keeffe EB. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation. Hepatology 2005;42:Suppl 1:593A. abstract.
13. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-8.
14. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-72.
15. Lok ASF, Lai C-L, Wu P-C, Leung EKY, Lam T-S. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839-43.
16. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24.
17. Chu C-J, Keeffe EB, Han S-Y, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003;125:444-51.
18. Chu C-J, Lok AS. Clinial significance of hepatitis B virus genotypes. Hepatology 2002;35:1274-6.
19. Kao J-H, Chen P-J, Lai M-Y, Chen D-S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9.
20. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9.
21. Manno M, Cammà C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004;127:756-63.
22. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982;96:447-9.
23. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991;100:182-8.
24. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
25. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
26. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993;119:312-23.
27. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
28. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alpha-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990;11:Suppl 1:S133-S136.
29. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003;23:81-8.
30. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
31. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
32. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
33. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
34. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-96.
35. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-26.
36. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-8.
37. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7. [Erratum, N Engl J Med 2003;348:1192.]
39. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.
40. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51.
41. Dusheiko G. Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B: a review of the major clinical studies. J Hepatol 2003;39:Suppl 1:S116-S123.
42. Chang T-T, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
43. Lai C-L, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8.
44. Lai C-L, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. [Erratum, N Engl J Med 2006;354:1863.]
45. Gish RG, Lok ASF, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44.
46. Dienstag JL, Wei L-J, Xu D, Kreter B. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007;27:35-49.
47. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36.
48. Lai C-L, Gane E, Liaw Y-F, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88.
49. Lai C-L, Gane E, Hsu C-W, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006;44:Suppl 1:222A. abstract.
50. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GSUS-174-0102. Hepatology 2007;46:Suppl 1:290A-1A. abstract.
51. Heathcote EJ, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HbeAg positive chronic hepatitis B (CHB): Study GSUS-174-0103. Hepatology 2007;46:Suppl 1:861A. abstract.
52. Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68.
53. Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103.
54. Perrillo R, Hann H-W, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
55. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
56. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-90.
57. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-7.
58. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55.
59. Ryu S-H, Chung Y-H, Choi M-H, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003;39:614-9.
60. Marcellin P, Bonino F, Lau GK, et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon α-2a (40kD) ± lamivudine: 3 years follow-up results. J Hepatol 2007;46:Suppl 1:S25-S26. abstract.
61. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
62. Rizzetto M, Tassopoulos NC, Goldin RD, et al. Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol 2005;42:173-9.
63. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
64. Kweon Y-O, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-55. [Erratum, J Hepatol 2002;36:714.]
65. Leung NWY, Lai CL, Liaw YF, et al. Lamivudine (100 mg qd) for 1 year significantly improves necroinflammatory activity and reduces progression in fibrosis stage: results of a placebo-controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection. Hepatology 1997;26:357A.
66. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
67. Malekzadeh R, Mohamadnejad M, Rakhshani N, et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2004;2:344-7.
68. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
69. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-10.
70. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-13.
71. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-7.
72. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411-6.
73. Villeneuve J-P, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
74. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival in 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433-9.
75. Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
76. Kim WR, Benson JT, Hindman A, Brosgart C, Fortner-Burton C. Decline in the need for liver transplantation for end stage liver disease secondary to hepatitis B in the US. Hepatology 2007;46:Suppl 1:238A. abstract.
77. Lok ASF, Lai C-L, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22.
78. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
79. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology 1998;28:1121-7.
80. Bourne EJ, Dienstag JL, Lopez VA, et al. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat 2007;14:55-63.
81. Lim SG, Ng TM, Kung N, et al. A doubleblind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166:49-56.
82. Chung YH, Lee KS, Kim JH, et al. Oneyear treatment with clevudine demonstrated significant viral suppression and biochemical improvement. J Hepatol 2006;44:Suppl 2:S25. abstract.
83. Yoo BC, Koh KC, Chung Y-H, et al. Clevudine is highly efficacious in HBeAg(-) chronic hepatitis B patients with a sustained antiviral effect after cessation of therapy. Hepatology 2005;42:Suppl 1:268A-269A. abstract.
84. Yoo BC, Kim JH, Lee KS, et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients. Hepatology 2005;42:Suppl 1:270A. abstract.
85. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-72.
86. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-49.
87. Colonno RJ, Rose RE, Pokornowski K, et al. Four-year assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients. J Hepatol 2007;46:Suppl 1:S294. abstract.
88. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007;132:1574-85.
89. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007;356:1445-54.
90. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007;46:254-65.
91. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008;134:405-15.
92. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003;39:Suppl 1:S124-S132.
93. Perrillo RP. Factors influencing response to interferon in chronic hepatitis B: implications for Asian and western populations. Hepatology 1990;12:1433-5.
94. Perrillo RP, Lai C-L, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002;36:186-94.
95. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-70. [Erratum, Hepatology 2004;40:767.]
96. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297-303.
97. Westland C, Delaney W IV, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-16.
98. Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757-62.
99. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7.
100. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13.
101. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-21.
102. Hirsch MS. Entecavir surprise. N Engl J Med 2007;356:2641-3.
103. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472-89.
104. EASL Jury. EASL International Consensus Conference on Hepatitis B: 13-14 September, 2002, Geneva, Switzerland: consensus statement (long version). J Hepatol 2003;39:Suppl 1:S3-S25.
105. Keeffe EB, Dieterich DT, Han S-HB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-62.
106. Lai C-L, Yuen M-F. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:58-61.
107. Degertekin B, Lok ASF. When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med 2007;147:62-4.
108. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-20.
109. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9.
110. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:432-8.
111. Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
112. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993;104:1116-21.
113. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995;109:908-16.
114. Perrillo RP. Therapy of hepatitis B - viral suppression or eradication? Hepatology 2006;43:Suppl 1:S182-S193.
115. Perrillo RP, Gish RG, Peters M, et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 2006;4:233-48.
116. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-19.
117. Suzuki Y, Kobayashi M, Ikeda K, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005;76:33-9.